证券代码：688180 证券简称：君实生物 公告编号：临 2024-027 上海君实生物医药科技股份有限公司 关于以集中竞价交易方式回购股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 截至 2024 年 4 月 30 日，公司通过上海证券交易所交易系统以集中竞价交易 方式已累计回购股份 781,486 股，占公司总股本比例为 0.0793%，回购成交的最高 价为人民币 41.69 元/股，最低价为人民币 29.21 元/股，支付的资金总额为人民币 29,883,225.58 元（不含印花税、交易佣金等交易费用）。本次回购股份进展符合法 律法规的规定及公司回购股份方案。 三、 其他事项 公司将严格按照《上市公司股份回购规则》《上海证券交易所上市公司自律监 管指引第 7 号——回购股份》等相关规定及公司回购股份方案，在回购期限内根 据市场情况择机做出回购决策并予以实施，同时根据回购股份事项进展情况及时 履行信息披露义务，敬请广大投资者注意投资风险。 特此公告。 上海君实生物医药科技股份有限公司 重要内容提示： ...

Investment Rating - The report maintains a "Buy" rating for the company, with a target price of 60.20 RMB, indicating an expected increase of over 15% relative to the CSI 300 index in the next six months [3][8]. Core Insights - The company reported a significant revenue growth of 49.24% year-on-year in Q1 2024, with total revenue reaching 381 million RMB, primarily driven by the sales of its core product, Toripalimab, which generated 307 million RMB in sales, reflecting a 56.82% increase [2][3]. - The company is expected to expand its domestic medical insurance indications to 10 by Q2 2024, with two new indications anticipated to be approved [2][3]. - The company has a strong cash position, with 4.559 billion RMB in cash as of March 31, 2024, which supports its operational efficiency and ongoing development [2][3]. Financial Projections - Projected revenues for 2024, 2025, and 2026 are 2.11 billion RMB, 3.44 billion RMB, and 4.70 billion RMB, respectively, with corresponding net profits expected to be -1.063 billion RMB, 12 million RMB, and 1.018 billion RMB [3][4]. - The report indicates a significant improvement in net profit margins, with a projected net profit growth rate of 8072.47% in 2026 [4][6]. Operational Efficiency - The company has improved its operational efficiency, with a reduction in R&D expenses by 47.64% year-on-year in Q1 2024, while maintaining sales and management expenses at manageable levels [2][3]. - The report highlights the company's focus on cost control and resource optimization, which has contributed to narrowing losses in the first quarter [2][3].

2024年04月30日 公 司点评 公 买入 / 维持 司 君实生物(688180) 研 究 目标价:60.20 昨收盘:27.95 拓益销售收入 Q1 同比增长 57%，适应症扩展成效显著 事件：  走势比较 近日，公司发布2024年第一季度报告。公司2024年第一季度营 业收入为 3.81 亿元（同比+49.24%），研发费用为 2.76 亿元（同比- 10% 47.64%），销售费用为1.92亿元（同比+4.91%），管理费用为1.23亿 太 平 (( 14 8% %))4/5/32 51/7/32 52/9/32 6/21/32 61/2/42 82/4/42 元 亿（ 元同 。比 +8.98%），归母净利润为-2.83亿元，扣非归母净利润为-3.07 洋 (32%) 证 观点： (46%) 券 2024Q1拓益销售收入大幅增长，公司整体运营效率提升，亏损收 (60%) 股 窄。2024 年第一季度公司营收 3.81亿元，同比增长 49.24%，营业收 份 君实生物 沪深300 入增长主要来自商业化药品销售收入的增长，其中，核心产品特瑞普 有  股票数据 利单抗于国内市场实现销售收入 3.07 亿 ...

Financial Performance - The company's operating revenue for Q1 2024 was RMB 380,804,271.07, representing a 49.24% increase compared to the same period last year[5] - The net profit attributable to shareholders was a loss of RMB 283,029,082.76, with a net profit excluding non-recurring items of RMB -307,067,930.26[5] - The company reported a weighted average return on net assets of -4.04%, an increase of 1.88 percentage points[5] - Total revenue for Q1 2024 reached ¥380,804,271.07, a significant increase from ¥255,154,522.24 in Q1 2023, representing a growth of approximately 49.2%[18] - Operating profit for Q1 2024 was reported at -¥292,835,633.87, an improvement compared to -¥633,218,295.88 in Q1 2023, indicating a reduction in losses[18] - Net loss for Q1 2024 was -¥299,647,965.46, compared to -¥639,619,944.79 in the same period last year, reflecting a decrease in net losses by about 53%[18] Cash Flow - The net cash flow from operating activities was RMB -376,577,871.82, indicating a significant cash outflow[5] - Cash inflow from operating activities totaled ¥399,332,111.78 in Q1 2024, up from ¥302,002,091.08 in Q1 2023, marking an increase of approximately 32.3%[20] - The net cash flow from operating activities for Q1 2024 was -$376.58 million, an improvement from -$720.25 million in Q1 2023, indicating a 47.7% reduction in cash outflow[21] - The total cash outflow for purchasing goods and services was ¥433,711,376.04 in Q1 2024, down from ¥562,535,881.61 in Q1 2023, reflecting a decrease of approximately 22.9%[20] - The company reported a total cash outflow from operating activities of $775.91 million, down from $1.02 billion in the same quarter last year, reflecting a 24.0% decrease[21] Research and Development - Research and development expenses totaled RMB 276,292,124.92, a decrease of 47.64% year-on-year[5] - The ratio of R&D expenses to operating revenue was 72.55%, down 134.25 percentage points from the previous year[6] - Research and development expenses for Q1 2024 were ¥276,292,124.92, down from ¥527,659,904.54 in Q1 2023, showing a reduction of about 47.6%[18] - The company has reduced losses compared to the same period last year by optimizing resource allocation and focusing on promising R&D pipelines[13] Assets and Liabilities - Total assets increased to RMB 12,024,485,796.49, up 6.01% from the end of the previous year[6] - The total current assets increased to CNY 6.19 billion, compared to CNY 5.57 billion at the end of 2023, reflecting a growth of approximately 11.2%[15] - Total liabilities increased to ¥5,005,671,597.96 in Q1 2024 from ¥4,022,256,399.35 in Q1 2023, representing an increase of approximately 24.5%[16] - The total equity attributable to shareholders decreased to ¥6,866,046,795.72 in Q1 2024 from ¥7,151,224,186.47 in Q1 2023, a decline of about 4%[16] Market and Product Development - The company's revenue from the core product, Toripalimab injection (brand name: Tuoyi®/LOQTORZI™), reached approximately CNY 306.86 million, representing a year-on-year growth of about 56.82%[13] - The company is advancing multiple late-stage pipeline projects, including JS002 (anti-PCSK9 monoclonal antibody) and JS005 (anti-IL-17A monoclonal antibody), to drive future revenue growth[14] - The company has received priority review designation for the marketing application of Toripalimab in Singapore for specific cancer treatments[13] - The number of indications for Toripalimab included in the national medical insurance directory has increased to 6, enhancing its market accessibility[13] - The company has established commercial partnerships in over 50 countries for Toripalimab, indicating strong international market expansion efforts[13] Inventory and Cash Management - The total inventory as of March 31, 2024, was CNY 535.55 million, slightly down from CNY 538.05 million at the end of 2023[15] - The company reported cash and cash equivalents of CNY 4.56 billion, up from CNY 3.79 billion in the previous quarter[15] - The total cash and cash equivalents at the end of Q1 2024 amounted to $4.55 billion, a decrease from $4.98 billion at the end of Q1 2023[21] - Cash received from borrowings in Q1 2024 was $1.28 billion, a substantial increase from $91.30 million in Q1 2023[21]

Financial Performance - The company's revenue for Q1 2024 was RMB 380,804,271.07, representing a 49.24% increase compared to the same period last year[4] - The net profit attributable to shareholders was a loss of RMB 283,029,082.76, with a net profit excluding non-recurring gains and losses of RMB -307,067,930.26[4] - The net cash flow from operating activities was RMB -376,577,871.82, indicating a negative cash flow situation[4] - The weighted average return on net assets was -4.04%, an increase of 1.88 percentage points compared to the previous year[4] - The company reported a total comprehensive loss of ¥298,795,396.58 in Q1 2024, compared to a loss of ¥667,067,229.83 in Q1 2023, reflecting a decrease of 55.2%[19] - Net loss for Q1 2024 was ¥299,647,965.46, an improvement from a net loss of ¥639,619,944.79 in Q1 2023, indicating a reduction of 53.1%[18] Research and Development - R&D investment totaled RMB 276,292,124.92, which decreased by 47.64% year-on-year[4] - The ratio of R&D investment to revenue was 72.55%, down 134.25 percentage points from the previous year[5] - Research and development expenses for Q1 2024 were ¥276,292,124.92, down 47.5% from ¥527,659,904.54 in Q1 2023[18] - The company has reduced its losses compared to the same period last year by optimizing resource allocation and focusing on promising R&D pipelines[13] Assets and Liabilities - Total assets at the end of the reporting period were RMB 12,024,485,796.49, an increase of 6.01% from the end of the previous year[5] - As of March 31, 2024, the total assets amounted to CNY 12,024.49 million, an increase from CNY 11,342.87 million as of December 31, 2023[15] - Total liabilities rose to ¥5,005,671,597.96 in Q1 2024 from ¥4,022,256,399.35 in Q1 2023, an increase of 24.5%[18] - The company's total equity decreased to ¥7,018,814,198.53 in Q1 2024 from ¥7,320,610,471.98 in Q1 2023, a decline of 4.1%[18] Cash Flow - Cash flow from operating activities increased to ¥399,332,111.78 in Q1 2024, compared to ¥302,002,091.08 in Q1 2023, marking a growth of 32.3%[19] - The net cash flow from operating activities was -$376.58 million, an improvement from -$720.25 million in the previous period, indicating a 47.7% reduction in cash outflow[21] - The company reported a cash outflow of $775.91 million from operating activities, which is a decrease of 24.1% compared to $1.02 billion in the previous period[21] - The cash outflow for investing activities was $237.35 million, down 74.5% from $925.64 million in the previous period, indicating a reduction in capital expenditures[21] Sales and Market Performance - The company reported a significant increase in pharmaceutical sales revenue, contributing to the overall revenue growth[7] - The company's revenue for the first quarter of 2024 reached approximately CNY 306.86 million, representing a year-on-year growth of about 56.82% driven primarily by the sales of the core product, Toripalimab injection (brand name: Tuoyi®/LOQTORZI™)[13] - Cash received from sales and services in Q1 2024 was ¥396,310,961.15, up from ¥231,060,650.60 in Q1 2023, representing an increase of 71.5%[19] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 32,331, with the largest shareholder holding 22.25% of the shares[10] - The company reported a total of 32,331 shareholders as of the report date, with 32,322 being A-share shareholders[12] Financing Activities - The net cash flow from financing activities was $1.22 billion, a substantial increase from $211.45 million in the previous period, showing a strong reliance on financing[21] - The company received $1.28 billion in cash from financing activities, primarily from loans, which significantly increased from $248.57 million in the prior period[21] - The company paid $30 million in debt repayment, which is an increase from $15 million in the previous period, reflecting a strategy to manage debt levels[21] Pipeline and Product Development - The company has received approval for 8 indications for Toripalimab in China and has established commercial partnerships in over 50 countries[13] - The company is advancing multiple late-stage pipeline projects, including JS002 (anti-PCSK9 monoclonal antibody) and JS005 (anti-IL-17A monoclonal antibody)[14] - The company has added 3 new indications for Tuoyi® to the national medical insurance catalog starting in 2024, bringing the total to 6 indications[13]

Financial Performance - For the year ended December 31, 2023, the total revenue of the group was approximately RMB 1,503 million, an increase of about 3% compared to the same period in 2022, primarily due to an increase in pharmaceutical product revenue[8] - The loss attributable to the owners of the company was RMB 2,282 million, a decrease of RMB 104 million compared to the same period in 2022[8] - For the fiscal year ending December 31, 2023, the company reported revenue of RMB 1,502.55 million, a decrease of 3.1% compared to RMB 1,453.49 million in 2022[17] - The gross profit for 2023 was RMB 835.26 million, reflecting a gross margin decline compared to RMB 927.21 million in 2022[17] - The total comprehensive expenses for the year were RMB 2,607.54 million, slightly lower than RMB 2,650.71 million in 2022[17] - The net loss from continuing operations for 2023 was RMB 2,533.88 million, compared to RMB 2,582.10 million in 2022, indicating a marginal improvement[17] - The company reported a decrease in share-based payment expenses by approximately 75% compared to the same period in 2022[103] - The adjusted total comprehensive expenses for the year ended December 31, 2023, were approximately RMB (2,581,895) thousand, compared to RMB (2,608,855) thousand for the year ended December 31, 2022[107] Research and Development - Research and development expenses totaled approximately RMB 1,937 million, a decrease of about 19% compared to the previous year, mainly due to the optimization of resource allocation and focus on more promising research pipelines[8] - The company has expanded its innovative research and development areas to include small molecule drugs, peptide drugs, antibody-drug conjugates (ADCs), bispecific or multispecific antibody drugs, and nucleic acid drugs, covering five major therapeutic areas[10] - The company has over 50 research and development pipelines, with several potential "first-in-class" products, enhancing its market position[21] - The product pipeline includes over 30 candidates in clinical trials and more than 20 in preclinical development, covering five major therapeutic areas[44] - The company is focusing on enhancing R&D efficiency and commercializing its pipeline products to strengthen its core competitiveness[23] Product Development and Approvals - The oral nucleoside analog drug, Mindewi® (Dezavirin), received conditional approval from NMPA in January 2023 for the treatment of mild to moderate COVID-19 in adult patients[10] - In April 2023, the sNDA for Tuoyi® as an adjuvant treatment for resectable stage IIIA-IIIB non-small cell lung cancer was accepted by NMPA, marking it as the first and only approved perioperative therapy for lung cancer in China[10] - In May 2023, the sNDA for Tuoyi® combined with paclitaxel (albumin-bound) for the treatment of PD-L1 positive (CPS≥1) first-line metastatic or recurrent triple-negative breast cancer was accepted by NMPA[12] - The NDA for Angorix monoclonal antibody was accepted by NMPA in April 2023, with multiple Phase III studies completed in various patient populations[38] - The IND application for JS401 was approved by NMPA in April 2023, marking a significant milestone in the development of siRNA drugs targeting ANGPTL3[92] Market Performance and Sales - During the reporting period, pharmaceutical revenue increased by approximately 58% year-on-year, with sales revenue of Tuoyi® (Tremelimumab) reaching approximately RMB 919 million, a 25% increase compared to 2022[8] - The company achieved significant sales growth in 2023, with three marketed products contributing increasingly to total revenue[21] - The sales revenue from pharmaceuticals has shown rapid growth, with the proportion of pharmaceutical sales in total revenue steadily increasing, indicating enhanced self-sustainability[32] - The company has expanded its commercialization team, significantly improving execution and sales efficiency, leading to positive sales progress for its products[32] Financial Position and Assets - The company’s total assets as of December 31, 2023, were RMB 11,362.46 million, a decrease from RMB 12,576.29 million in 2022[18] - Non-current assets increased to RMB 5,812.64 million in 2023 from RMB 5,371.38 million in 2022[18] - The total liabilities rose to RMB 4,022.26 million in 2023, up from RMB 2,782.04 million in 2022[18] - The company’s total assets as of 2023 were RMB 11,342,867 thousand, a decrease from RMB 12,558,496 thousand in 2022, indicating a need for strategic asset management[19] Corporate Governance and Management - The company has appointed several independent directors with diverse backgrounds in law, finance, and healthcare, enhancing governance and strategic oversight[182][186] - The management team includes Dr. Zou Jianjun as CEO, Mr. Li Cong as Co-CEO, and several other vice presidents with diverse expertise in their respective fields[195] - The board includes members with extensive backgrounds in clinical medicine and pharmaceutical management, enhancing strategic decision-making[162] - The company emphasizes the importance of governance and compliance, with a dedicated audit committee overseeing financial integrity[182] Strategic Initiatives and Future Plans - The company plans to enter into a licensing agreement with Excellmab for the exclusive development and commercialization of Tuoyi® in several Southeast Asian countries, with potential milestone payments of up to approximately USD 4.52 million[15] - The company aims to enhance its competitiveness through the development and commercialization of innovative drugs in international markets[113] - The company is exploring potential mergers and acquisitions to strengthen its market position and expand its product offerings[170] - The strategic committee is focused on long-term growth and innovation in the biopharmaceutical sector[162]

2024年4月24日，上海君实生物医药科技股份有限公司（以下简称"公司"） 董事会收到陈英格女士的书面辞呈，因职业发展原因，陈英格女士申请辞去公司 董事会秘书、联席公司秘书和授权代表职务，辞呈自送达公司董事会之日起生效。 陈英格女士辞职后，将不再担任公司任何职务。 证券代码：688180 证券简称：君实生物 公告编号：临 2024-024 上海君实生物医药科技股份有限公司 关于变更董事会秘书、联席公司秘书 及授权代表的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会秘书、联席公司秘书及授权代表辞任情况 陈英格女士在担任公司董事会秘书、联席公司秘书和授权代表期间勤勉尽责、 恪尽职守，对公司发展作出了重要贡献，公司董事会对陈英格女士任职期间的工 作表示衷心感谢。 二、董事会秘书、联席公司秘书及授权代表变更情况 上海君实生物医药科技股份有限公司 王征宇先生的个人简历详见附件，联系方式如下： 电话：021-61058800-1153 传真：021-61757377 邮箱：info@junshipharma.com ...

上海君实生物医药科技股份有限公司 自愿披露关于特瑞普利单抗上市许可申请 获得香港卫生署药物办公室受理的公告 证券代码：688180 证券简称：君实生物 公告编号：临 2024-023 POLARIS-02 研究结果已于 2021 年 1 月在线发表于《临床肿瘤学杂志》 （Journal of Clinical Oncology，影响因子：45.3）。研究结果显示，特瑞普利单 抗在既往化疗失败的复发/转移性鼻咽癌患者中表现出持久的抗肿瘤活性和可控 的安全性，患者客观缓解率（ORR）为 20.5%，中位缓解持续时间（DoR）为 12.8 个月，中位 OS 达 17.4 个月。 特瑞普利单抗注射液是中国首个批准上市的以 PD-1 为靶点的国产单抗药物， 曾荣膺国家专利领域最高奖项"中国专利金奖"，至今已在全球（包括中国、美 国、东南亚及欧洲等地）开展了覆盖超过 15 个适应症的 40 多项由公司发起的临 床研究。正在进行或已完成的关键注册临床研究在多个瘤种范围内评估特瑞普利 单抗的安全性及疗效。截至本公告披露日，特瑞普利单抗的 8 项适应症已于中国 内地获批。2020 年 12 月，特瑞普利单抗注射液首次通过国家医 ...

海通证券股份有限公司 关于上海君实生物医药科技股份有限公司 2023 年度持续督导年度跟踪报告 | 保荐机构名称：海通证券股份有限公司 | 被保荐公司简称：君实生物 | | --- | --- | | 保荐代表人姓名：崔浩、陈新军 | 被保荐公司代码：688180.SH | 1 公开发行股票，每股面值人民币 1 元，每股发行价格人民币 55.50 元，募集资金 总额为人民币 483,571.50 万元，扣除发行费用后，实际募集资金净额为人民币 449,697.83 万元。首次公开发行证券已于 2020 年 7 月 15 日在上海证券交易所上 市。海通证券股份有限公司（以下简称"保荐机构"或"海通证券"）担任其持 续督导保荐机构，持续督导期间为 2022 年 3 月 28 日至 2023 年 12 月 31 日。 重大事项提示 2023 年度，上海君实生物医药科技股份有限公司（以下简称"君实生物"、 "上市公司"或"公司"）实现营业收入 150,254.99 万元，较去年同期增长 3.38%； 实现归母净利润-228,343.19 万元，去年同期为-238,804.99 万元；实现扣非后净 利润-229,755 ...

海通证券股份有限公司 关于上海君实生物医药科技股份有限公司 2023 年度持续督导现场检查报告 上海证券交易所： 经中国证券监督管理委员会《关于同意上海君实生物医药科技股份有限公 司首次公开发行股票注册的批复》（证监许可[2020]940 号）批复，上海君实生 物医药科技股份有限公司（以下简称"君实生物"、"上市公司"、"公司"）首次 公开发行股票 8,713.00 万股，每股面值人民币 1 元，每股发行价格人民币 55.50 元，募集资金总额为人民币 4,835,715,000.00 元，扣除发行费用后，实际募集资 金净额为人民币 4,496,978,326.73 元。本次发行证券已于 2020 年 7 月 15 日在上 海证券交易所上市。海通证券股份有限公司（以下简称"海通证券"、"保荐机构"） 担任其持续督导保荐机构，持续督导期间为 2022 年 3 月 28 日至 2023 年 12 月 31 日。 根据《证券发行上市保荐业务管理办法》《上海证券交易所科创板股票上市 规则》《上海证券交易所上市公司自律监管指引第 11 号——持续督导》《上海证 券交易所科创板上市公司自律监管指引第 1 号——规范运作》 ...